According to the NCI website, Crizanlizumab is a humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Check for active clinical trials using this agent. (NCI Thesaurus)

Indikationen/Anwendungsmöglichkeiten gemäss PDR:

• Used to reduce the frequency of vasoocclusive crises in patients with sickle cell disease
  Monitor for infusion-related reactions and interference with automated platelet counts

More Information in English:

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute

Wiki
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)